The global pleural disease therapeutics market is poised for significant growth, with a projected valuation of USD 9.4 billion by 2033, according to a recently published study by Future Market Insights. Registering a steady CAGR of 6.5% over the next decade, the market is expected to rise from USD 4.98 billion in 2023.
This growth is driven by the increasing prevalence of critical health conditions such as congestive heart failure, lung diseases, pneumonia, cancer, and tuberculosis. As these conditions often lead to pleural effusion—a buildup of fluid in the pleural cavity—the demand for effective treatments and diagnostics is escalating worldwide. Delayed diagnosis of pleural effusion can lead to severe morbidity and mortality, underscoring the urgent need for advanced therapeutic procedures.
Key Drivers of Market Growth:
- Rising Incidence of Pleural Effusion-Related Diseases:
Conditions such as systemic lupus erythematosus (30%-50% of patients) and idiopathic pulmonary hypertension (21.5% of patients) exhibit a high association with pleural effusion. This surge in cases is expected to bolster demand for pleural disease therapeutics globally.
- Advancements in Diagnosis and Expertise:
Enhanced diagnostic techniques and the availability of skilled healthcare professionals specializing in pleural effusion treatment are pivotal in driving market expansion.
- Innovative Product Launches and Strategic Developments:
Leading market players are investing heavily in R&D and strategic collaborations. For instance, in September 2021, BDR Pharma introduced BIAPENEM, a groundbreaking therapeutic solution for treating intra-abdominal infections, lower respiratory infections, and complex urinary tract infections. The drug’s efficacy in penetrating lung tissues and body fluids such as pleural effusion has positioned it as a vital innovation in pleural disease therapeutics.
Future Outlook:
The increasing focus on early diagnosis and innovative treatment solutions is expected to sustain the momentum of the Pleural Disease Therapeutics Market over the forecast period. Additionally, ongoing investments, mergers, and product launches by key industry players will further accelerate market growth.
As healthcare systems worldwide prioritize addressing critical respiratory and cardiac conditions, the demand for advanced pleural disease therapeutics is anticipated to remain robust, positioning this market as a vital component of global healthcare advancements.
Rising Interest in Market Trends: Our Detailed Report Provides Essential Insights!
Key Takeaways from the Market Study:
- North America is expected to dominate the industry while reaching market share of around 45% by end of the forecast period
- The market in Europe is projected to account for 29% market share during the projected timeline
- By treatment type, thoracentesis is projected to account for 34% market share by end of the forecast period
- Hospitals are expected to dominate the market by end-user, with a market share of 65 % by 2033
- Global market for pleural disease therapeutics to reach USD 4.98 billion by the end of 2023
“Adoption of novel drugs and mergers and acquisitions between companies are going to positively influence market of Pleural disease therapeutics during the forecast period,” comments an FMI analyst.
Competitive Landscape:
The Pleural diseases therapeutics market is moderately competitive and consists of various key market players. These players are creating novel delivery systems for treating Pleural diseases. This is anticipated to fuel Pleural diseases therapeutics market. The key players in the market are: WakeMed Health and Hospitals, Boston Medical, Max Healthcare, Avik Pharma, Pfizer CentreOne, Hovione, Pipelinepharma, Hoffmann-La Roche AG, Boehringer Ingelheim International GmbH, Bausch Health Companies Inc., Sanofi S.A.
Key market players are focusing on adoption of inorganic growth strategies such as acquisition, partnerships, and collaboration in order to enhance their product portfolio. This is expected to propel the global Pleural diseases therapeutics market.
- In September 2021, Bristol Mayer Squibb announced three-year data from the Checkmate -743 trial. According to the clinical trial data, serious adverse reactions occurred in almost 54% of patients receiving OPDIVO plus YERVOY. The most frequent serious adverse reactions reported in ≥2% of patients were pneumonia, pyrexia, diarrhea, pneumonitis, pleural effusion, dyspnea, acute kidney injury, infusion-related reaction, musculoskeletal pain, and pulmonary embolism.
- In January 2020, Argon Medical launched single and triple loop retrieval kits for its U.S. market with the aim to improve lives of patients. The products have managed to secure the approval from the United States Food and Drug Administration, and are efficient in the removal of retrievable IVC filters with the help of a jugular approach. These single and triple loop retrieval kits are the only 2 kits to have received FDA approval in terms of any retrievable IVC filter from a jugular approach.
Key Segments Profiled in the Pleural Diseases Therapeutics Industry Survey:
By Treatment:
- Drug Class
- Antibiotics
- Antifungals
- Corticosteroids
- Narcotic Analgesics
- Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- Bullectomy
- Chemotherapy
- Video-Assisted Thorascopic Surgery (VATS)
- PleurX Catheter
- Pleurodesis Therapy
- Radiation Therapy
- Thoracentesis
- Thoracostomy
By End Users:
- Hospitals
- Specialty Clinics
- Others
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East and Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube